Amplyx Pharmaceuticals Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
26
- Latest Deal Type
-
M&A
Amplyx Pharmaceuticals General Information
Description
Developer of antifungal agents intended to treat invasive fungal infections. The company's agents use both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenience therapy after discharge from the hospital, enabling patients undergoing chemotherapy and other immunosuppressive therapies, with compromised immune systems, to get proper treatment for life-threatening invasive fungal infections due to Candida, Aspergillus, and rare molds.
Contact Information
Website
www.amplyx.comCorporate Office
- 12730 High Bluff Drive
- Suite 160
- San Diego, CA 92130
- United States
Corporate Office
- 12730 High Bluff Drive
- Suite 160
- San Diego, CA 92130
- United States
Amplyx Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 05-Apr-2021 | Completed | Generating Revenue | |||
| 7. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 6. Later Stage VC (Series C) | 09-Jan-2020 | Completed | Generating Revenue | |||
| 5. Grant | 18-Aug-2017 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 27-Jun-2017 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 01-Jan-2011 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Jan-2008 | Completed | Startup | |||
| 1. Angel (individual) | 30-Oct-2007 | Completed | Startup |
Amplyx Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 8,243,027 | $0.001000 | 8% | $0.27 | $0.27 | 1x | $0.27 | 2.04% |
Amplyx Pharmaceuticals Comparisons
Industry
Financing
Details
Amplyx Pharmaceuticals Competitors (20)
One of Amplyx Pharmaceuticals’s 20 competitors is F2G, a Venture Capital-Backed company based in Macclesfield, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| F2G | Venture Capital-Backed | Macclesfield, United Kingdom | ||||
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA | ||||
| Gangagen Biotechnologies | Venture Capital-Backed | Bangalore, India | ||||
| Iconic Therapeutics | Formerly VC-backed | South San Francisco, CA |
Amplyx Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Amplyx Pharmaceuticals Patents
Amplyx Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021257670-A1 | Compounds and methods for treating fungal infections | Inactive | 17-Jun-2020 | ||
| WO-2021252835-A1 | Dosing of polyomavirus neutralizing antibodies | Inactive | 12-Jun-2020 | ||
| WO-2021178406-A1 | Use of compounds in the treatment of fungal infections | Inactive | 04-Mar-2020 | ||
| WO-2020247804-A1 | Heterocycle substituted pyridine derivative antifungal agents | Inactive | 07-Jun-2019 | ||
| WO-2020047510-A1 | Compounds and methods for treating fungal infections | Inactive | 31-Aug-2018 | A61K31/675 |
Amplyx Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Amplyx Pharmaceuticals Former Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 503 Partners | Venture Capital | Minority | ||
| Adage Capital Management | Hedge Fund | Minority | ||
| Angel (individual) | Minority | |||
| Ariel Savannah Angel Partners | Angel Group | Minority | ||
| Arix Bioscience | Venture Capital | Minority |
Amplyx Pharmaceuticals FAQs
-
When was Amplyx Pharmaceuticals founded?
Amplyx Pharmaceuticals was founded in 2006.
-
Where is Amplyx Pharmaceuticals headquartered?
Amplyx Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of Amplyx Pharmaceuticals?
Amplyx Pharmaceuticals has 26 total employees.
-
What industry is Amplyx Pharmaceuticals in?
Amplyx Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Amplyx Pharmaceuticals a private or public company?
Amplyx Pharmaceuticals is a Private company.
-
What is Amplyx Pharmaceuticals’s current revenue?
The current revenue for Amplyx Pharmaceuticals is .
-
How much funding has Amplyx Pharmaceuticals raised over time?
Amplyx Pharmaceuticals has raised $143M.
-
Who are Amplyx Pharmaceuticals’s investors?
503 Partners, Adage Capital Management, , Ariel Savannah Angel Partners, and Arix Bioscience are 5 of 24 investors who have invested in Amplyx Pharmaceuticals.
-
Who are Amplyx Pharmaceuticals’s competitors?
F2G, Spero Therapeutics, CytoAgents, Gangagen Biotechnologies, and Iconic Therapeutics are some of the 20 competitors of Amplyx Pharmaceuticals.
-
When was Amplyx Pharmaceuticals acquired?
Amplyx Pharmaceuticals was acquired on 05-Apr-2021.
-
Who acquired Amplyx Pharmaceuticals?
Amplyx Pharmaceuticals was acquired by Pfizer.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
